348 related articles for article (PubMed ID: 20144017)
1. Review of meningococcal group B vaccines.
Granoff DM
Clin Infect Dis; 2010 Mar; 50 Suppl 2(S2):S54-65. PubMed ID: 20144017
[TBL] [Abstract][Full Text] [Related]
2. Challenges and progress in the development of a serogroup B meningococcal vaccine.
Lewis S; Sadarangani M; Hoe JC; Pollard AJ
Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.
Koeberling O; Giuntini S; Seubert A; Granoff DM
Clin Vaccine Immunol; 2009 Feb; 16(2):156-62. PubMed ID: 19109451
[TBL] [Abstract][Full Text] [Related]
4. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
[TBL] [Abstract][Full Text] [Related]
5. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
Pajon R; Lujan E; Granoff DM
Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
[TBL] [Abstract][Full Text] [Related]
6. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
[TBL] [Abstract][Full Text] [Related]
7. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
[TBL] [Abstract][Full Text] [Related]
8. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
Holst J
Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
[TBL] [Abstract][Full Text] [Related]
9. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).
Koeberling O; Ispasanie E; Hauser J; Rossi O; Pluschke G; Caugant DA; Saul A; MacLennan CA
Vaccine; 2014 May; 32(23):2688-95. PubMed ID: 24704334
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Gandhi A; Balmer P; York LJ
Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
[TBL] [Abstract][Full Text] [Related]
12. [Meningococcal serogroup B vaccines].
Dommergues MA
Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
[TBL] [Abstract][Full Text] [Related]
13. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.
Giuntini S; Pajon R; Ram S; Granoff DM
Infect Immun; 2015 Apr; 83(4):1536-45. PubMed ID: 25644002
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
[TBL] [Abstract][Full Text] [Related]
15. Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness.
Poolman JT; Richmond P
Expert Rev Vaccines; 2015; 14(9):1277-87. PubMed ID: 26204792
[TBL] [Abstract][Full Text] [Related]
16. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.
Lucidarme J; Comanducci M; Findlow J; Gray SJ; Kaczmarski EB; Guiver M; Vallely PJ; Oster P; Pizza M; Bambini S; Muzzi A; Borrow R
Clin Vaccine Immunol; 2010 Jun; 17(6):919-29. PubMed ID: 20375242
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
[TBL] [Abstract][Full Text] [Related]
18. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.
Koeberling O; Delany I; Granoff DM
Clin Vaccine Immunol; 2011 May; 18(5):736-42. PubMed ID: 21367981
[TBL] [Abstract][Full Text] [Related]
19. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
Marsay L; Dold C; Green CA; Rollier CS; Norheim G; Sadarangani M; Shanyinde M; Brehony C; Thompson AJ; Sanders H; Chan H; Haworth K; Derrick JP; Feavers IM; Maiden MC; Pollard AJ
J Infect; 2015 Sep; 71(3):326-37. PubMed ID: 25982025
[TBL] [Abstract][Full Text] [Related]
20. Bexsero: a multicomponent vaccine for prevention of meningococcal disease.
Gorringe AR; Pajón R
Hum Vaccin Immunother; 2012 Feb; 8(2):174-83. PubMed ID: 22426368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
